The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.
See here for further details on the change. Please also see our June 23, 2020 article for a summary of notable changes in the revised draft Guidelines.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Pharmaceutical and Life Sciences Sector Task Force submits final report to the Ministers of Health and Industry
On July 24, 2026, the Pharmaceutical and Life Sciences Sector Task Force (the “Task Force”) published its final report to the Ministers of Health and Industry pursuant to a mandate to (i) explore inno...Read More -
Canada’s Drug Agency: guidance document on use of AI methods & summary of precision medicine initiatives
In July 2026, Canada’s Drug Agency (CDA) published Use of Artificial Intelligence Methods to Generate Real-World Evidence Submitted to Canada’s Drug Agency for HTA. This guidance document describes pr...Read More -
PMPRB consults further on revised proposed practice directions
The Patented Medicine Prices Review Board (PMPRB) holds public hearings on two types of mattersRead More
